Adjunctive technologies in treatment of patients with urogenital tuberculosis
- Authors: Shevchenko S.Y.1, Kulchavenya E.B.1,2
-
Affiliations:
- TB Research Institute of Ministry of Health of Russia
- Novosibirsk State Medical University of Ministry of Health of Russia
- Issue: No 3 (2019)
- Pages: 50-53
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/303636
- DOI: https://doi.org/10.18565/urology.2019.3.50-53
- ID: 303636
Cite item
Open Access
Access granted
Abstract
Introduction. Currently, the limits of therapeutic efficiency in urogenital tuberculosis have been achieved. The etiological therapy should be supplement by pathogenetic drugs. Aim: to determine the efficiency of deoxyribonucleate sodium in the complex treatment of patients with urogenital tuberculosis. Material and methods. Single-center open-label randomized comparative prospective study was carried out. A total of 62 patients with active urogenital tuberculosis were included. All patients received therapy in accordance with National clinical guidelines for urogenital tuberculosis. In the main group, patients additionally received pathogenetic therapy in form of deoxyribonucleate sodium via intramuscular injection of 75 mg every 48 hours. Whole one-month course consisted of 15 injections. Pathogenetic therapy was started immediately after the choosing of anti- tuberculosis drugs and confirmation of good tolerability. The efficiency of treatment was evaluated after one and three months. The assessed criteria included the intensity of pain and severity of dysuria, signs of inflammation, bacterial isolation and changes in the quality of life. Conclusion. The addition of deoxyribonucleate sodium in the form of intramuscular injections of 75 mg every 48 hours for 1 months resulted in a significant increase in the efficiency of treatment. Quality of life in patients receiving deoxyribonucleate sodium improved twice (from 11.1 to 21.5 points), while in the control group this value was twice as low (from 10.8 to 15.9 points).
Keywords
Full Text
About the authors
S. Yu Shevchenko
TB Research Institute of Ministry of Health of Russia
Email: urotub@yandex.ru
Ph.D., senior researcher
E. B. Kulchavenya
TB Research Institute of Ministry of Health of Russia; Novosibirsk State Medical University of Ministry of Health of Russia
Email: urotub@yandex.ru
MD, professor, Principal Research Fellow; professor at Department of Tuberculosis
References
- Kulchavenya E., Zhukova I., Kholtobin D. Spectrum of Urogenital Tuberculosis. J. Infect Chemother. 2013;19(5):880-883.
- Kulchavenya E., Naber K. Johansen T.E.B. Influence of HIV Infection on Spectrum of Extrapulmonary Tuberculosis. J. Infect Dis Ther. 2018;6:377. doi: 10.4172/2332-0877.1000377.
- Figueiredo A.A., Lucon A.M., Srougi M. Urogenital Tuberculosis. Microbiol Spectr. 2017;5(1). doi: 10.1128/microbiolspec.TNMI7-0015-2016.
- Кульчавеня Е. В., Краснов В.А., Мордык А.В. Альманах внелёгочного туберкулёза. Новосибирск: Сибпринт, 2015. 247 с.: илл. ISBN 978-5-94301-579-3
- Fomicheva E.E., Filatenkova T.A., Shanin S.N., Rybakina E.G. Stress-induced changes in the functional activity of the neuroendocrine system: the modulatory activity of derinat. Neurosci Behav Physiol. 2010;40(4):397- 401. doi: 10.1007/s11055-010-9270-z.
- Hsu W.L., Lu J.H., Noda M., Wu C.Y., Liu J.D., Sakakibara M., Tsai M.H., Yu H.S., Lin M.W., Huang Y.B., Yan S.J., Yoshioka T. Derinat Protects Skin against Ultraviolet-B (UVB)-Induced Cellular Damage. Molecules. 2015;20(11):20297-20311. doi: 10.3390/molecules201119693.
- Ishii-Mizuno Y., Umeki Y., Onuki Y., Watanabe H., Takahashi Y., Takakura Y., Nishikawa M. Improved sustained release of antigen from immunostimulatory DNA hydrogel by electrostatic interaction with chitosan. Int J. Pharm. 2017;516(1-2):392-400. Doi: 10.1016/j. ijpharm.2016.11.048.
- Nishikawa M., Ogawa K., Umeki Y., Mohri K., Kawasaki Y., Watanabe H., Takahashi N., Kusuki E., Takahashi R., Takahashi Y., Takakura Y. Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. J. Control Release. 2014;180:25-32. doi: 10.1016/j.jconrel.2014.02.001.
- Nomura D., Saito M., Takahashi Y., Takahashi Y., Takakura Y., Nishikawa M. Development of Orally-deliverable DNA Hydrogel by Microemulsification and Chitosan Coating. Int J. Pharm. 2018 Jun 11. pii: S0378-5173(18)30427-7. doi: 10.1016/j.ijpharm.2018.06.029.
- Земсков А.М., Журихина И.И., Добросоцких Г.В., Коруняк Д.И., Толмачева А.В., Земскова В.А. Комплексная иммунотерапия - перспективный метод лечения гнойно-воспалительных заболеваний. Вестник новых медицинских технологий. 2013;20(1):152-154
- Кузьменко В.В., Кузьменко А.В., Золотухин О.В., Мадыкин Ю.Ю., Кочетов М.В., Семенов Б.В., Аносова Ю.А. Иммунокорригирующая терапия больных мочекаменной болезнью и хроническим пиелонефритом при дистанционной литотрипсии. Саратовский научно-медицинский журнал. 2011;7(S2):47-51
- Federal'ny'e klinicheskie rekomendacii po diagnostike i lecheniyu urogenital'nogo tuberkuleza available on http://roftb.ru/netcat_files/ doks2015/rec5.pdf (Федеральные клинические рекомендации по диагностике и лечению урогенитального туберкулеза. http://roftb.ru/ netcat_files/doks2015/rec5.pdf).
- Каракулова О.А., Савинова Т.А., Мишук В.П., Башкатов В.А., Горячева С.А. Изучение качества жизни больных инфильтративным туберкулезом легких. Бюллетень физиологии и патологии дыхания. 2012;3:70-73
Supplementary files
